Your browser is no longer supported. Please, upgrade your browser.
OLMA [NASD]
Olema Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own4.20% Shs Outstand39.61M Perf Week-8.38%
Market Cap259.19M Forward P/E- EPS next Y-2.48 Insider Trans59.24% Shs Float35.92M Perf Month-28.23%
Income-59.60M PEG- EPS next Q-0.50 Inst Own93.50% Short Float10.68% Perf Quarter-76.98%
Sales- P/S- EPS this Y-455.80% Inst Trans2.27% Short Ratio4.52 Perf Half Y-74.22%
Book/sh7.60 P/B0.86 EPS next Y-41.70% ROA-18.30% Target Price46.25 Perf Year-84.73%
Cash/sh7.74 P/C0.85 EPS next 5Y- ROE-18.60% 52W Range6.27 - 54.88 Perf YTD-29.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.05% Beta-
Dividend %- Quick Ratio34.60 Sales past 5Y- Gross Margin- 52W Low4.63% ATR0.71
Employees60 Current Ratio34.60 Sales Q/Q- Oper. Margin- RSI (14)22.31 Volatility7.64% 8.27%
OptionableYes Debt/Eq0.00 EPS Q/Q-24.30% Profit Margin- Rel Volume0.50 Prev Close6.69
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume849.16K Price6.56
Recom1.60 SMA20-23.55% SMA50-54.82% SMA200-73.16% Volume423,233 Change-1.94%
Dec-07-21Resumed Cowen Outperform
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Dec-14-20Initiated Cowen Outperform
Dec-14-20Initiated Canaccord Genuity Buy $60
Jan-04-22 07:30AM  
Dec-16-21 12:38PM  
Dec-01-21 04:09PM  
Nov-30-21 11:02AM  
07:00AM  
Nov-29-21 04:27PM  
Nov-22-21 07:30AM  
Nov-19-21 12:00PM  
Nov-10-21 04:05PM  
Nov-09-21 07:30AM  
Oct-18-21 11:01AM  
Oct-13-21 11:43AM  
Sep-30-21 05:00PM  
Sep-09-21 07:30AM  
Aug-30-21 04:05PM  
Aug-18-21 10:46AM  
Aug-10-21 04:05PM  
Jul-28-21 04:05PM  
May-18-21 04:05PM  
May-11-21 04:05PM  
Apr-07-21 07:30AM  
Apr-06-21 07:30AM  
Mar-17-21 04:05PM  
Mar-10-21 04:45PM  
Feb-23-21 07:00AM  
Feb-19-21 04:59AM  
Dec-31-20 03:42PM  
Dec-17-20 07:00AM  
Dec-07-20 07:39AM  
Dec-03-20 05:18PM  
Nov-23-20 04:01PM  
Nov-20-20 01:33PM  
Nov-19-20 06:39PM  
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Horn KinneyCHIEF BUSINESS OFFICERJan 10Option Exercise2.065,25110,8387,709Jan 11 08:21 PM
Horn KinneyCHIEF BUSINESS OFFICERJan 10Sale6.855,25135,9692,458Jan 11 08:21 PM
Horn KinneyCHIEF BUSINESS OFFICERDec 10Option Exercise2.065,25110,8387,709Dec 14 04:25 PM
Horn KinneyCHIEF BUSINESS OFFICERDec 10Sale10.395,25154,5582,458Dec 14 04:25 PM
Myles David C.CHIEF DEVELOPMENT OFFICERDec 10Sale10.3010,000103,000582,901Dec 14 04:03 PM
BVF PARTNERS L P/ILDirectorNov 30Buy9.39739,6756,945,7703,755,093Dec 02 08:45 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERNov 29Sale24.764009,9041,051,146Dec 01 05:34 PM
Horn KinneyCHIEF BUSINESS OFFICERNov 10Option Exercise15.7927,668436,76129,458Nov 12 05:15 PM
Horn KinneyCHIEF BUSINESS OFFICERNov 10Sale26.8827,668743,7161,790Nov 12 05:15 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICEROct 19Sale27.9812,000335,7941,051,546Oct 21 04:33 PM
Bohen SeanPRESIDENT AND CEOOct 14Option Exercise4.825,00024,12057,514Oct 15 06:44 PM
Bohen SeanPRESIDENT AND CEOOct 14Sale30.475,000152,36352,514Oct 15 06:44 PM
Horn KinneyCHIEF BUSINESS OFFICEROct 11Option Exercise2.065,25110,8387,041Oct 12 06:53 PM
Horn KinneyCHIEF BUSINESS OFFICEROct 11Sale27.905,251146,5101,790Oct 12 06:53 PM
Bohen SeanPRESIDENT AND CEOSep 27Option Exercise4.821,0855,23453,599Sep 29 07:56 PM
Bohen SeanPRESIDENT AND CEOSep 27Sale30.071,08532,62652,514Sep 29 07:56 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERSep 20Sale26.3012,000315,6001,063,546Sep 21 06:19 PM
Horn KinneyCHIEF BUSINESS OFFICERSep 10Option Exercise2.065,25110,8387,041Sep 13 08:07 PM
Horn KinneyCHIEF BUSINESS OFFICERSep 10Sale29.385,251154,2741,790Sep 13 08:07 PM
Bohen SeanPRESIDENT AND CEOSep 08Option Exercise4.822,63112,69256,905Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 08Sale30.002,63178,93052,514Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 07Option Exercise4.824131,99254,687Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 07Sale30.0841312,42354,274Sep 09 04:25 PM
Bohen SeanPRESIDENT AND CEOSep 01Option Exercise4.828714,20255,145Sep 03 05:16 PM
Bohen SeanPRESIDENT AND CEOSep 01Sale30.0587126,17454,274Sep 03 05:16 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERAug 19Sale24.9712,000299,6401,075,546Aug 20 09:14 PM
Horn KinneyCHIEF BUSINESS OFFICERAug 10Option Exercise2.065,25110,8387,041Aug 11 06:05 PM
Horn KinneyCHIEF BUSINESS OFFICERAug 10Sale25.715,251134,9791,790Aug 11 06:05 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERJul 20Sale25.634,123105,6721,087,546Jul 21 05:29 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERJul 19Sale24.837,877195,5861,091,669Jul 21 05:29 PM
Horn KinneyCHIEF BUSINESS OFFICERJul 12Option Exercise2.065,25110,8387,041Jul 13 06:27 PM
Horn KinneyCHIEF BUSINESS OFFICERJul 12Sale26.515,251139,1911,790Jul 13 06:27 PM
Harmon CyrusCHIEF TECHNOLOGY OFFICERJun 18Sale24.8012,000297,6261,099,546Jun 21 07:05 PM
Horn KinneyCHIEF BUSINESS OFFICERJun 10Option Exercise2.065,25110,8387,041Jun 11 04:30 PM
Horn KinneyCHIEF BUSINESS OFFICERJun 10Sale29.725,251156,0711,790Jun 11 04:30 PM
Horn KinneyCHIEF BUSINESS OFFICERMay 18Option Exercise2.0657,763119,22359,553May 19 08:18 PM
Horn KinneyCHIEF BUSINESS OFFICERMay 18Sale24.1557,7631,394,7691,790May 19 08:18 PM